RSV is a common respiratory infection that typically occurs during the colder months. The infection can be particularly dangerous in children younger than 5 and in adults over the age of 65. According to the Centers for Disease Control and Prevention, between 100 and 300 children under 5 and between 6,000 to 10,000 older adults die each year from RSV infections.
Scientists have tried to develop an RSV vaccine for years, but only recently have those research efforts led to clinical successes. Along with GSK, Pfizer and Moderna, Johnson & Johnson, Sanofi and Bavarian Nordic are also testing RSV vaccines.
